Wszystkie zdjęcia(1)
Kluczowe dokumenty
L1295
Lamivudine
≥98% (HPLC), powder
Synonim(y):
2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wybierz wielkość
Wybierz wielkość
Zmień widok
About This Item
Wzór empiryczny (zapis Hilla):
C8H11N3O3S
Numer CAS:
Masa cząsteczkowa:
229.26
Numer MDL:
Kod UNSPSC:
12352200
Identyfikator substancji w PubChem:
NACRES:
NA.77
Polecane produkty
Poziom jakości
Próba
≥98% (HPLC)
Formularz
powder
kolor
white to beige
rozpuszczalność
water: 10 mg/mL, clear
inicjator
GlaxoSmithKline
temp. przechowywania
room temp
ciąg SMILES
NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
InChI
1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
Klucz InChI
JTEGQNOMFQHVDC-NKWVEPMBSA-N
Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów
Zastosowanie
Lamivudine has been used to deplete the Hepatitis B Virus (HBV) covalently closed circular DNA (cccDNA) forms for the preparation of inverse nested PCR.
Działania biochem./fizjol.
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.
Cechy i korzyści
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Hasło ostrzegawcze
Warning
Zwroty wskazujące rodzaj zagrożenia
Zwroty wskazujące środki ostrożności
Klasyfikacja zagrożeń
Repr. 2
Kod klasy składowania
11 - Combustible Solids
Klasa zagrożenia wodnego (WGK)
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
Chia-Yen Dai et al.
The Journal of antimicrobial chemotherapy, 68(10), 2332-2338 (2013-06-27)
For hepatitis B e antigen (HBeAg)-positive patients, continuing therapy (consolidation) for 6-12 months before cessation of nucleos(t)ide analogues (NAs) was recommended. This study aimed to investigate whether a longer period of lamivudine consolidation therapy leads to better outcomes and the
Raph L Hamers et al.
Journal of acquired immune deficiency syndromes (1999), 64(2), 174-182 (2013-07-31)
This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes. A multicenter prospective cohort of HIV-infected
Wai-Kay Seto et al.
Hepatology (Baltimore, Md.), 58(3), 923-931 (2013-03-08)
The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our
Kiyoaki Ito et al.
Hepatology (Baltimore, Md.), 59(1), 89-97 (2013-07-31)
The proportion of patients who progress to chronicity following acute hepatitis B (AHB) varies widely worldwide. Moreover, the association between viral persistence after AHB and hepatitis B virus (HBV) genotypes in adults remains unclear. A nationwide multicenter study was conducted
Edward J Gane et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(3), 268-274 (2013-03-01)
Without effective prophylaxis, liver transplantation for hepatitis B virus (HBV)-related liver disease is frequently complicated by severe and rapidly progressive HBV recurrence. Combination prophylaxis with hepatitis B immune globulin (HBIG) and lamivudine (LAM) reduces long-term recurrence rates below 10%; however
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej